Amedeo Smart

Free Medical Literature Service



Cytomegalovirus Infection

  Free Subscription

Articles published in
Antimicrob Agents Chemother
    June 2021
  1. ZARROUK K, Zhu X, Pham VD, Goyette N, et al
    Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
    Antimicrob Agents Chemother. 2021;65:e0039021.
    >> Share

    February 2021
  2. NGUYEN T, Oualha M, Briand C, Bendavid M, et al
    Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

    December 2020
  3. SU H, Ye X, Freed DC, Li L, et al
    A potent bispecific neutralizing antibody targeting glycoprotein B and the gH/gL/pUL128/130/131 complex of human cytomegalovirus.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02422.
    >> Share

    October 2020
  4. HAMILTON ST, Marschall M, Rawlinson WD
    Investigational antiviral therapy models for the prevention and treatment of congenital cytomegalovirus infection during pregnancy.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01627.
    >> Share

    July 2020
  5. MERCORELLI B, Luganini A, Celegato M, Palu G, et al
    The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication.
    Antimicrob Agents Chemother. 2020 Jul 20. pii: AAC.00056.
    >> Share

    February 2020
  6. ZARROUK K, Pham VD, Piret J, Shi R, et al
    Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.01910.
    >> Share

  7. MAERTENS J, Logan AC, Jang J, Long G, et al
    Anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation: a phase 2 study.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02467.
    >> Share

    May 2019
  8. TURNER NA, Wolfe CR
    Reply to Frange and Leruez-Ville, "Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases".
    Antimicrob Agents Chemother. 2019;63.
    >> Share

  9. FRANGE P, Leruez-Ville M
    Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases.
    Antimicrob Agents Chemother. 2019;63.
    >> Share

    March 2019
  10. RITCHIE BM, Barreto JN, Barreto EF, Crow SA, et al
    Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety.
    Antimicrob Agents Chemother. 2019;63.
    >> Share

    January 2019
  11. TURNER N, Strand A, Grewal DS, Cox G, et al
    Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series.
    Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.02337.
    >> Share

    October 2018
  12. WANG Y, Mukhopadhyay R, Roy S, Kapoor A, et al
    Inhibition of Cytomegalovirus Replication with Extended Half-Life Synthetic Ozonides.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01735.
    >> Share

    June 2018
  13. CHOU S, Satterwhite LE, Ercolani RJ
    A New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by in vitro Exposure to Letermovir and Ganciclovir.
    Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00922.
    >> Share

    April 2018
  14. OIKNINE-DJIAN E, Weisblum Y, Panet A, Wong HN, et al
    The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.
    Antimicrob Agents Chemother. 2018 Apr 30. pii: AAC.00288.
    >> Share

    March 2018
  15. DONG Q, Leroux S, Shi HY, Xu HY, et al
    Model-based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection: A Pilot Study.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.00075.
    >> Share

    November 2017
  16. DENG R, Wang Y, Maia M, Burgess T, et al
    Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anti-cytomegalovirus monoclonal antibodies, in a Phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01108.
    >> Share

    October 2017
  17. MENG W, Tang A, Ye X, Gui X, et al
    Targeting Human Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-gB Bispecific Antibody.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01719.
    >> Share

    August 2017
  18. CHOU S
    Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
    Antimicrob Agents Chemother. 2017 Aug 21. pii: AAC.01325.
    >> Share

  19. PIRET J, Goyette N, Boivin G
    Drug Susceptibility and Replicative Capacity of Multi-Drug Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01044.
    >> Share

    November 2016
  20. ISHIDA JH, Patel A, Mehta AK, Gatault P, et al
    Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01794.
    >> Share

    April 2016
  21. PADULLES A, Colom H, Bestard O, Melilli E, et al
    Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
    Antimicrob Agents Chemother. 2016;60:1992-2002.
    >> Share

    November 2015
  22. VAZQUEZ JA, Manavathu EK
    Molecular Characterization of a Voriconazole-resistant, Posaconazole-susceptible, Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States.
    Antimicrob Agents Chemother. 2015 Nov 16. pii: AAC.01130.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016